Abstract Submission & Guidelines

Late Breaking Abstract Submission is now closed

Deadline: Tuesday, August 24, 2021 – 23:59 – Eastern Standard Time

KEY DATES

*Note all efforts are made to send notifications by the planned date. Should there be any delays with the selection process, revised dates will be posted here

Rules for Submission

Please read the submission rules before submitting an abstract.

• Abstracts must be submitted online via the website only.
  ABSTRACTS SUBMITTED BY EMAIL WILL NOT BE ACCEPTED.
• Presentation Type: Abstracts may be submitted for oral or Poster. Late breaking submission will be submitted ONLY for Oral pretension.
• Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.

LIMITATIONS

• Prospective multicenter trials as well as presentation of large translational works are considered as major quality criteria. Inter-diseases sessions (such as target, pathway or immunology oriented) will be planned.
• Case reports and small institutional series of limited added scientific value are not encouraged.
• Clinical Trials in Progress Abstracts cannot be submitted
• Shell Abstracts (abstracts that provide no data) cannot be submitted
  A shell abstract is one that intends to have data but the data are either not collected yet or analyzed yet. Qualitative data are appropriate to submit.
• Previous Publications of an Abstract – an abstract can be submitted if it was/will be presented at a scientific meeting in the current year (2021). If it was presented in 2020 or earlier, then it cannot be submitted unless there is significant new data.
• The same person may submit up to 5 abstracts regardless of presenting author.
• The same person may serve as presenting author on up to 5 abstracts.
• Presenting authors must be registered participants. Only abstracts of authors who have paid their registration fees by the date indicated in the notification email will be scheduled for presentation and included for publication.
• Submission of an abstract acknowledges your acceptance for the abstract to be published in the official Congress publications.
• The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
• Abstracts must be submitted in English.
  All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. Authors who would like assistance with the English writing of their abstract, should contact us at least 2 weeks prior the deadline.
• Disclosure of Conflicts of Interest: Abstract submitters will be required to disclose any conflict of interests in the submission form.
• Instructions for preparation of presentations will be made available on the congress website.
• All accepted abstracts that their presenting author has registered by the deadline indicated in the notification email (Excluding Late Breaking Abstracts) will be published in the Pediatric Blood and Cancer (PBC) online supplement.

GUIDELINES FOR SUBMISSION

​Before you begin, please prepare the following information:

• ​Presenting author’s contact details:
  – Full first and family name(s)
  – Email address
  – Affiliation details: department, institution / hospital, city state (if relevant), Country
  – Phone number
• Author and co-authors’ details
• Preferred Presentation type: Oral Presentation/Poster
• Abstract title – must be in UPPER CASE and limited to 25 words. Please submit symbols as words.
• Abstract text – limited to 300 words including acknowledgements.
• Abstract topic– select the abstract topic per the list of topics.
• Text only is to be submitted. Tables, figures and bulleted text are not permitted.
• Abstracts should clearly state:
  Background and aims
  Methods
  Results
  Conclusions 
• Use only standard abbreviations. Abbreviations must be consistent with instructions to authors of the Pediatric Blood & Cancer Journal and be defined on 1st usage, then use of abbreviation alone is OK, i.e. Wilms Tumor (WT), then referred to as “WT” in subsequent mention. Please use as few abbreviations as possible and only commonly used abbreviations.
• Disease names should be written without apostrophes, for example: Wilms tumour, Burkitt lymphoma, Hodgkin disease, etc. Please do not refer to patients by their diseases, e.g. ‘Wilms tumour patients’ or ALL patients’. Instead identify them as ‘patients with Wilms tumour; and ‘patients with ALL’.
• Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
• Submissions may not contain patient names, hospital ID numbers or other identifying information.
• Numbers over 999 must include a comma, e.g., 2,000.
• Decimal points must be displayed as periods (4.89) not commas (4,89).
• Numbers beginning with a decimal point should be preceded by a zero.
• Periods should be used in numbers for decimal points, not commas, i.e. P=0.015
• All measurements must be in metric units.
• Do not begin sentences with a number – type the number in full, for example, it should be ‘Three patients….’ Instead of ‘3 patients….’.
• Do not use expressions such as ‘On the other hand……’; ‘This is the first study….’; ‘To our knowledge…..’; ‘This is the largest….’.
• Abstracts stating “data will be discussed in the presentation” will NOT be accepted.
• Click on the SUBMIT button at the end of the process in order to save your abstract. You may log in to the system later to make changes to your abstract, up to the submission deadline. After the deadline, changes will not be possible.
• You will receive an abstract reference number via email after you have submitted your abstract. Please refer to this abstract number in all correspondence regarding the abstract.
• Please contact us if you have not received confirmation that your abstract has been submitted.
• Please do not submit multiple copies of the same abstract.

ABSTRACT SUBMITTERS’ DECLARATION

During abstract submission you will be asked to confirm that you agree to the following:

• I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published as submitted.
• Submission of the abstract constitutes the consent of all authors to publication (e.g. Congress website, programs, other promotions, etc.)
• The Abstract Submitter warrants and represents that no part of the information and content provided by him/her (Hereafter: the “Content“) to SIOP 2020 and Kenes International (Hereafter: the “Organizers“), nor the publication of any such Content by the Organizers, on the internet or otherwise infringes any third party rights, including but not limited to privacy rights and/or intellectual property rights.
• The Abstract Submitter grants the Organizers a copyright license to reproduce, publish, translate, distribute, and display the text of the Content on a royalty-free, perpetual, irrevocable nonexclusive basis.
• I herewith confirm that the contact details saved in this system are those of the presenting author, who will be notified about the status of the abstract. The presenting author is responsible for informing the other authors about the status of the abstract. The submitting author may request to be copied on abstract correspondence.
• I understand that the presenting author must be a registered participant.
• The Organizers reserve the right to remove from publication and/or presentation an abstract which does not comply with the above.
• I understand that I must select a specific Theme, Topic and/or Sub-Topic for my abstract allocation.  Although the Committee will work hard to honor this selection, this cannot be guaranteed.  The Committee reserves the right to change the Theme, Topic or Sub-Topic under which the abstract was originally submitted.

SELECTION PROCESS

All abstracts will be evaluated anonymously and scored by the appropriate SPAC members. The Scientific Committee will determine whether the abstract will be accepted for presentation, with consideration given to the author’s preference.
The Scientific Committee will determine If accepted as:

• an oral presentation;
• a poster presentation, possibly with a poster session participation or special Scientific Committee mention;
• a journal publication